CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic

Checkpoint blocking antibodies targeting regulatory molecules on T cells such as CTLA-4 and PD-1 have reinvigorated the field of cancer immunotherapy. These agents have demonstrated clinical activity across a variety of tumor types. Now that safety and clinical activity has been demonstrated in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Callahan, Margaret K., Postow, Michael A., Wolchok, Jedd D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295550/
https://www.ncbi.nlm.nih.gov/pubmed/25642417
http://dx.doi.org/10.3389/fonc.2014.00385
_version_ 1782352863584845824
author Callahan, Margaret K.
Postow, Michael A.
Wolchok, Jedd D.
author_facet Callahan, Margaret K.
Postow, Michael A.
Wolchok, Jedd D.
author_sort Callahan, Margaret K.
collection PubMed
description Checkpoint blocking antibodies targeting regulatory molecules on T cells such as CTLA-4 and PD-1 have reinvigorated the field of cancer immunotherapy. These agents have demonstrated clinical activity across a variety of tumor types. Now that safety and clinical activity has been demonstrated in the monotherapy setting, the field is moving in the direction of testing novel combinations.
format Online
Article
Text
id pubmed-4295550
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-42955502015-01-30 CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic Callahan, Margaret K. Postow, Michael A. Wolchok, Jedd D. Front Oncol Oncology Checkpoint blocking antibodies targeting regulatory molecules on T cells such as CTLA-4 and PD-1 have reinvigorated the field of cancer immunotherapy. These agents have demonstrated clinical activity across a variety of tumor types. Now that safety and clinical activity has been demonstrated in the monotherapy setting, the field is moving in the direction of testing novel combinations. Frontiers Media S.A. 2015-01-15 /pmc/articles/PMC4295550/ /pubmed/25642417 http://dx.doi.org/10.3389/fonc.2014.00385 Text en Copyright © 2015 Callahan, Postow and Wolchok. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Callahan, Margaret K.
Postow, Michael A.
Wolchok, Jedd D.
CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
title CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
title_full CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
title_fullStr CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
title_full_unstemmed CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
title_short CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
title_sort ctla-4 and pd-1 pathway blockade: combinations in the clinic
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295550/
https://www.ncbi.nlm.nih.gov/pubmed/25642417
http://dx.doi.org/10.3389/fonc.2014.00385
work_keys_str_mv AT callahanmargaretk ctla4andpd1pathwayblockadecombinationsintheclinic
AT postowmichaela ctla4andpd1pathwayblockadecombinationsintheclinic
AT wolchokjeddd ctla4andpd1pathwayblockadecombinationsintheclinic

Ejemplares similares